Supplementary Figures 1-7 from Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figures 1-7 - PDF file 117K, Supplementary Figure 1. Cohorts used for BCI model training and validation Supplementary Figure 2. Performance of H:I and MGI for early (0-5 years) and late (> 5 years) distant recurrence in Stockholm ER+, LN- untreated patients. A, C: H:I, 0-5 years and > 5 years. B, D: MGI, 0-5 years and > 5 years. Supplementary Figure 3. BCI risk groups for prediction of overall distant recurrence in Stockholm TAM and Multi-institutional cohorts, ER+, LN- patients. Supplementary Figure 4. Continuous BCI score for overall (0 - 10 years) rate of distant recurrence in Stockholm TAM cohort. Supplementary Figure 5. BCI risk groups for prediction of early and late distant recurrence in the combined StockholmTAM and Multi-institutional cohort; ER+, LN-, tamoxifen-treated patients. Supplementary Figure 6. Continuous BCI score for early (0 - 5 years) and late (> 5 years) rate of distant recurrence in the combined Stockholm TAM and Multi-institutional cohort (ER+, LN-, tamoxifen-treated patients). Supplementary Figure 7. Prediction of tamoxifen benefit by H/I. A: no benefit of tamoxifen in H/I-low patients. B: benefit of tamoxifen in H/I-high patients
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361882279